TITLE

E-cadherin as a prognostic indicator in primary breast cancer

AUTHOR(S)
Parker, C; Rampaul, R S; Pinder, S E; Bell, J A; Wencyk, P M; Blamey, R W; Nicholson, R I; Robertson, J F R
PUB. DATE
December 2001
SOURCE
British Journal of Cancer;12/15/2001, Vol. 85 Issue 12, p1958
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Epithelial cadherin (E-CD) is a member of the cadherin family of cell adhesion molecules and has been implicated as an invasion suppressor molecule in vitro and in vivo. We analysed 174 breast tumours from the Nottingham/Tenovus Breast Cancer Series immunohistochemically for E-CD expression using the mouse monoclonal antibody HECD-1 (Zymed Laboratories Inc.). In normal epithelial cells E-CD was strongly expressed at cell-cell boundaries. 66% of the breast cancers examined had reduced intensity of E-CD expression with 74% having significant reductions in the proportion of E-CD-positive tumour cells. Using a combined intensity/proportion score, significant associations were found between E-CD expression and tumour type (P ≤ 0.001). ER status (P = 0.026) and histological grade (P = 0.031). Expression of E-CD was not found to be related to recurrence, distant metastases, lymph node stage, vascular invasion, primary tumour size, prognostic group or survival. Thus E-CD expression in human breast cancer appears to have minimal prognostic value, but may have a role as a phenotypic marker.
ACCESSION #
8877042

 

Related Articles

  • Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. de Mascarel, I.; MacGrogan, G.; Picot, V.; Mathoulin-Pelissier, S. // British Journal of Cancer;7/1/2002, Vol. 87 Issue 1, p70 

    Axillary lymph node metastases detected by immunohistochemistry in standard node-negative patients with breast carcinomas (13 out of 129 infiltrating ductal carcinomas and 37 out of 89 infiltrating Iobular carcinomas) do not have any prognostic significance in patients followed up for a long...

  • OCT4 Expression and Vasculogenic Mimicry Formation Positively Correlate with Poor Prognosis in Human Breast Cancer. Tieju Liu; Baocun Sun; Xiulan Zhao; Yanlei Li; Qiang Gu; Xueyi Dong; Fang Liu // International Journal of Molecular Sciences;2014, Vol. 15 Issue 11, p19634 

    To evaluate the prognostic value of OCT4 expression and vasculogenic mimicry (VM) in human breast cancer, we examined OCT4 expression and VM formation using immunohistochemistry and CD31/PAS (periodic acid-schiff) double staining on 90 breast cancer specimens. All patients were followed up for...

  • Multicentric and multifocal versus unifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology. Weissenbacher, Tobias; Hirte, Eva; Kuhn, Christina; Janni, Wolfgang; Mayr, Doris; Karsten, Uwe; Rack, Brigitte; Friese, Klaus; Jeschke, Udo; Heublein, Sabine; Dian, Darius; Ditsch, Nina // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: The aim of this study was to evaluate the expression of the cell adhesion-related glycoproteins MUC-1, β-catenin and E-cadherin in multicentric/multifocal breast cancer in comparison to unifocal disease in order to identify potential differences in the biology of these tumor...

  • Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. Dan Zhou; Shao-Qiang Cheng; Hong-Fei Ji; Jin-Song Wang; Hai-Tao Xu; Guo-Qiang Zhang; Da Pang // Journal of Cancer Research & Clinical Oncology;Nov2010, Vol. 136 Issue 11, p1719 

    Purpose: Angiogenesis, which plays an important role in tumor growth and metastasis, is regulated by a balance between angiogenic stimulators and inhibitors. Pigment epithelium-derived factor (PEDF), a secreted glycoprotein is an important inhibitor of angiogenesis. Although the precise...

  • Predicting aggressive outcome in T1N0M0 breast cancer. Kronqvist, P.; Kuopio, T.; Nykänen, M.; Helenius, H.; Anttinen, J.; Klemi, P. // British Journal of Cancer;7/19/2004, Vol. 91 Issue 2, p277 

    Despite the excellent overall prognosis, unpredictable breast cancer recurrences and deaths also occur among T1N0M0 patients. We have evaluated clinically applicable methods for identifying aggressive outcome in T1N0M0 breast cancer. The material is based on aggressive T1N0M0 invasive ductal and...

  • Girdin protein: a new potential distant metastasis predictor of breast cancer. Liu, Caigang; Zhang, Yanjun; Xu, Hong; Zhang, Ruishan; Li, Hua; Lu, Ping; Jin, Feng // Medical Oncology;Sep2012, Vol. 29 Issue 3, p1554 

    To investigate the expression status and the clinical implications of Girdin protein in breast cancer. The expression status of Girdin protein and clinicopathological parameters in 820 breast cancer specimens was analyzed using immunohistochemistry staining and the relationship between Girdin...

  • Prognostic Factors for Carcinoma of the Male Breast. Gattuso, Paolo; Reddy, Vijaya B.; Green, Linda K.; Castelli, Melanie J.; Wick, Mark R. // International Journal of Surgical Pathology;Jan1995, Vol. 2 Issue 3, p199 

    Male mammary carcinoma (MMC) affects approximately 1000 men in the United States each year. Aside from the impact of estrogen-receptor positivity on the clinical course of this tumor, relatively little information exists in published form on the ability of special pathologic studies to predict...

  • Expression of Estrogen Receptor Beta and Phosphorylation of Estrogen Receptor Alpha Serine 167 Correlate with Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Aromatase Inhibitors. Motomura, Kazuyoshi; Ishitobi, Makoto; Komoike, Yoshifumi; Koyama, Hiroki; Nagase, Hideki; Inaji, Hideo; Noguchi, Shinzaburo // Oncology;2010, Vol. 79 Issue 1/2, p55 

    Aromatase inhibitor (AI) is widely used as an endocrine treatment in postmenopausal patients with hormone receptor-positive breast cancer. To identify useful prognostic factors for patients with metastatic breast cancer treated with AI therapy, we investigated the association between several...

  • Prognostic Value of Syndecan-1 Expression in Breast Cancer. Leivonen, Marja; Lundin, Johan; Nordling, Stig; Von Boguslawski, Kristina; Haglund, Caj // Oncology;2004, Vol. 67 Issue 1, p11 

    Objective: Syndecan-1 is a cell surface heparan sulphate proteoglycan which participates in cell proliferation, cell migration and cell-matrix interactions. Epithelial syndecan-1 expression is reduced in several malignant tumours, but in breast and pancreatic cancer, increased expression has...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics